Madrigal Pharmaceuticals (NASDAQ:MDGL) Releases Earnings Results, Beats Estimates By $0.98 EPS

Madrigal Pharmaceuticals (NASDAQ:MDGL) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($3.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.23) by $0.98, FiscalAI reports. Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The firm had revenue of $311.34 million for the quarter, compared to the consensus estimate of $301.05 million. During the same period last year, the firm earned ($3.32) earnings per share. The company’s quarterly revenue was up 126.8% on a year-over-year basis.

Here are the key takeaways from Madrigal Pharmaceuticals’ conference call:

• Rezdiffra reached $1.1 billion LTM net sales with Q1 revenue of $311M and >42,250 active patients (2.5x YoY), and management says Q2 momentum is strong.
• The U.S. addressable MASH market has expanded ~50% to ~460,000 diagnosed F2/F3 patients, with diagnosis rates and drug penetration still low (<~10%), implying substantial runway for future growth.
• Madrigal is running an event?driven F4?C outcomes trial (potentially doubling the opportunity to ~245,000 patients) with a planned readout in 2027 and supportive open?label data showing improvement in CSPH?related risk metrics.
• The company has expanded its pipeline to >10 programs (including the newly in?licensed siRNA ARO?PNPLA3 showing up to 46% liver fat reduction in Phase I) while increasing R&D and SG&A spending, widening the net loss and reducing cash to ~$818M—supportive of long?term upside but with near?term cost impact.

Madrigal Pharmaceuticals Stock Up 7.4%

Shares of NASDAQ:MDGL traded up $37.26 during trading on Wednesday, reaching $539.73. The stock had a trading volume of 569,273 shares, compared to its average volume of 255,738. Madrigal Pharmaceuticals has a one year low of $265.00 and a one year high of $615.00. The company has a market capitalization of $12.44 billion, a P/E ratio of -41.94 and a beta of -1.04. The company has a current ratio of 4.01, a quick ratio of 3.77 and a debt-to-equity ratio of 0.56. The firm’s 50-day simple moving average is $486.52 and its 200 day simple moving average is $506.47.

Key Stories Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat consensus — MDGL reported EPS of ($3.25) vs. estimates for a larger loss and revenue of $311.3M, topping forecasts and showing strong year?over?year revenue growth. This underpinning of near?term commercial traction is a key reason shares are higher. Zacks: Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
• Positive Sentiment: Rezdiffra sales growth and expanded MASH strategy — coverage highlights that accelerating Rezdiffra net sales and a broadening pipeline are validating Madrigal’s MASH-focused commercial strategy, boosting confidence in revenue runway. MSN: Madrigal’s MASH Strategy Reinforced By Rezdiffra Sales Growth and Pipeline Expansion
• Positive Sentiment: License of ARO?PNPLA3 (siRNA) from Arrowhead — the exclusive deal adds a clinical?stage, genetically targeted asset that showed strong Phase 1 liver?fat reductions in PNPLA3 homozygotes, strengthening Madrigal’s precision-MASH pipeline and potential addressable market. Yahoo: Should Madrigal’s ARO-PNPLA3 License Deal Reshape the MASH Strategy
• Positive Sentiment: Analyst support — HC Wainwright reaffirmed a “buy” and set a $620 price target, implying material upside vs. the prior price level and lending credibility to the bull case. Benzinga: HC Wainwright Reaffirms Buy on Madrigal
• Neutral Sentiment: Company presentation and call provide detail — management’s Q1 slide deck and earnings call transcript outline commercial performance, expense cadence, and pipeline timelines; useful for modeling but not a single catalyst. Seeking Alpha: Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Corporate filings and press releases — company’s official Q1 release and pipeline announcement provide primary-source detail for investors building forecasts. GlobeNewswire: Q1 2026 Financial Results and Corporate Updates
• Negative Sentiment: Profitability still distant — despite the beat, Madrigal remains unprofitable with negative net margin/ROE and consensus still forecasting multi?dollar negative EPS for the fiscal year; long?term valuation depends on durable Rezdiffra growth and successful development of new assets. Stamford Advocate: Madrigal Q1 Earnings Snapshot

Insiders Place Their Bets

In other news, Director Rebecca Taub sold 491 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $431.94, for a total value of $212,082.54. Following the sale, the director directly owned 452,213 shares in the company, valued at approximately $195,328,883.22. This trade represents a 0.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William John Sibold sold 1,663 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $431.94, for a total transaction of $718,316.22. Following the completion of the sale, the chief executive officer owned 161,829 shares in the company, valued at $69,900,418.26. This represents a 1.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 6,098 shares of company stock worth $2,626,254. Insiders own 21.50% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Centaurus Financial Inc. boosted its stake in Madrigal Pharmaceuticals by 5.0% in the 3rd quarter. Centaurus Financial Inc. now owns 709 shares of the biopharmaceutical company’s stock worth $325,000 after purchasing an additional 34 shares in the last quarter. HighTower Advisors LLC boosted its stake in Madrigal Pharmaceuticals by 4.1% in the 4th quarter. HighTower Advisors LLC now owns 1,173 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 46 shares in the last quarter. Orion Porfolio Solutions LLC boosted its stake in Madrigal Pharmaceuticals by 1.3% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 3,638 shares of the biopharmaceutical company’s stock worth $1,101,000 after purchasing an additional 47 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Madrigal Pharmaceuticals by 50.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 187 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 63 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in Madrigal Pharmaceuticals in the 4th quarter worth approximately $39,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MDGL has been the topic of a number of recent research reports. The Goldman Sachs Group reiterated a “buy” rating and set a $571.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 14th. Barclays initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 27th. They set an “overweight” rating and a $964.00 price objective on the stock. Bank of America dropped their price objective on shares of Madrigal Pharmaceuticals from $570.00 to $529.00 and set a “neutral” rating on the stock in a research note on Friday, February 20th. Zacks Research upgraded shares of Madrigal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Finally, Wolfe Research set a $579.00 price target on shares of Madrigal Pharmaceuticals in a report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $685.31.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-? agonist in Phase 3 development for the treatment of NASH.